Table 4.

Meta-analyses on the thromboembolic risk with various angiogenesis inhibitors in ovarian cancer.

Author, Year [Ref]	Therapeutic Agents Included	Total Included Patients	All TE RR (95% CI)	VTE RR (95% CI)	ATE RR (95% CI)
Zhou, 2013 [55]	bevacizumab	3621	NA	1.32 (0.99–1.75) p = 0.054	2.29 (1.33–3.75) p < 0.03
Wang, 2014 [60]	bevacizumab	3608	1.85 (1.18–2.91)	NA	NA
Li, 2015 [56]	bevacizumab	3621	NA	NA	2.33 (1.34–4.03) p = 0.003
Yi, 2017 [57]	bevacizumab	3211	NA	NA	4.84 (1.24–12.98) p = 0.03
Wu, 2017 [59]	bevacizumab	4994	NA	1.43 (1.04–1.96) p = 0.03	2.39 (1.39–4.10) p = 0.002
Wang, 2018 [58]	Bevacizumab, sorafenib, nintedanib, pazopanib, aflibercept	8721	NA	1.08 (0.79–1.48)	2.27 (1.34–3.84)
Our analysis	bevacizumab	6119	NA	1.32 (1.02–1.78) p = 0.04	2.45 (1.27–4.72) p = 0.009

VTE: venous thromboembolism; ATE: arterial thromboembolism; RR: risk ratio; CI: confidence interval; NA: not available.